Chemotherapy-induced neuropathic pain characteristics in Mexico’s National Cancer Center pain clinic

Figures & data

Table 1 Demographic and cancer features between groups

	Total sample n=754 n, %	OSNP group n=521 n, %	CINP group n=233 n, %	Statistics
Demographic features and medical comorbidities
Sex-Women	525, 69.6	356, 68.3	169, 72.5	x^2=1.3, p=0.24
Diabetes-Yes^a	142, 18.9	99, 19.1	43, 18.5	x^2=0.03, p=0.86
Hypertension-Yes^a	186, 24.8	131 25.2	55 23.7	x^2=0.2, p=0.65
Thyroid disease-Yes	36, 4.8	27, 5.2	9, 3.9	x^2=0.6, p=0.43
Autoimmune disease-Yes^a	16, 2.1	10, 1.9	6, 2.6	x^2=0.3, p=0.56
Alcohol-Yes^b	92, 12.3	62, 12.0	30, 12.9	x^2=0.1, p=0.71
Smoker-Yes^b	160, 21.3	108, 20.8	52, 22.4	x^2=0.2, p=0.62
Type of cancer, stage of progression and chemotherapy agents
Breast	217, 28.8	143, 27.4	74, 31.8	x^2=19.3, p=0.002
Hematologic malignencies	91, 12.1	53, 10.2	38, 16.3
Cervix	42, 5.6	22, 4.2	20, 8.6
Lung	79, 10.5	62, 11.9	17, 7.3
Colon	14, 1.9	9, 1.7	5, 2.1
Other	311, 41.2	232, 44.5	79, 33.9
Progression^c
Stage 1	31, 5.1	23, 5.5	8, 4.0	x^2=40.3, p<0.001
Stage 2	72, 11.7	48, 11.6	24, 33.3
Stage 3	149, 24.3	82, 19.8	67, 33.8
Stage 4	250, 40.8	161, 38.8	89, 44.9
Chemotherapy agents^d
Platins	112, 15.0	52, 10.0	60, 26.1	x^2=32.2, p<0.001
Cisplatins	80, 10.7	44, 8.5	36, 15.7	x^2=8.5, p=0.003
Vincristine	31, 4.1	15, 2.9	16, 7.0	x^2=6.6, p=0.01
Paclitaxel	127, 17.0	39, 7.5	88, 38.3	x^2=106.7, p<0.001
Docetaxel	43, 5.7	24, 4.6	19, 8.3	x^2=3.8, p=0.06
Thalidomide	37, 4.9	17, 3.3	20, 8.7	x^2=9.9, p=0.002
Lenalidomide	2, 0.3	–	2, 0.09	x^2=4.5, p=0.09
Other	355, 47.5	198, 38.2	157, 68.3	x^2=57.6, p<0.001
	Mean, S.D.	Mean, S.D.	Mean, S.D.
Age	59.0, 14.1	59.4, 14.8	58.0, 12.4	t=1.2, p=0.21

Notes: ^an=751 ^bn=750 ^cn=613 ^dn=748.

Table 2 Pain characteristics patients with chemotherapy-induced neuropathic pain and patients with other types of pain

	Total sample n=754 n, %	OSNP group n=521 n, %	CINP group n=233 n, %	Statistics
Pain assessment^a
Tingling	333, 46.5	209, 42.0	124, 56.9	x^2=13.5, p<0.001
Numbness	326, 45.5	209, 42.0	117, 53.7	x^2=8.3, p=0.004
Electric shock-like	310, 43.3	202, 40.6	108, 49.5	x^2=4.9, p=0.02
Pinprick pain	300, 41.9	196, 39.4	104, 47.4	x^2=4.3, p=0.03
Burning	261, 36.5	171, 34.3	90, 41.3	x^2=3.1, p=0.08
Tactile hypoesthesia	148, 20.7	90, 18.1	58, 26.6	x^2=6.7, p=0.009
Itch	109, 15.2	75, 15.1	34, 15.6	x^2=0.03, p=0.85
Cold allodynia	108, 15.1	69, 13.9	39, 17.9	x^2=1.9, p=0.16
General allodynia	100, 14.0	61, 12.2	39, 17.9	x^2=4.0, p=0.04
Pinprick hypoesthesia	60, 8.4	35, 7.0	25, 11.5	x^2=3.8, p=0.06
Pain distribution^b
Unidentified	39, 5.8	38, 8.5	1, 0.4
Glove/Stocking	192, 28.4	25, 5.6	167, 72.9	x^2=339.9, p<0.001
Surgery site	77, 11.4	66, 14.8	11, 4.8
Tumor site	201, 29.7	173, 38.7	28, 12.2
Other	167, 24.7	144, 32.4	22, 9.6
	Mean, S.D.	Mean, S.D.	Mean, S.D.
DN4 score^c	2.8, 2.2	2.6, 2.2	3.3, 2.2	t=−3.7, p<0.001

Notes: ^an=716, ^bn=676, ^cn=715.

Table 3 Pain perception and management during a year attending the Pain Management Clinic

	Total sample n=752 n, %	OSNP group n=519 n, %	CINP group n=233 n, %	Statistics
Tramadol
Admission	290, 38.6	184, 35.5	106, 45.5	x^2=6.8, p=0.009
1-year	219, 29.2	147, 71.7	72, 31.0	x^2=0.5, p=0.45
Tapentadol
Admission	2, 0.3	2, 0.4	–	x^2=0.9, p=0.34
1-year	6, 0.8	5, 1.0	1, 0.4	x^2=0.5, p=0.44
Morphine
Admission	204, 27.1	147, 28.3	57, 24.5	x^2=1.2, p=0.27
1-year	259, 34.5	169, 32.6	90, 38.8	x^2=2.7, p=0.09
Oxycodone
Admission	23, 3.1	14, 2.7	9, 3.9	x^2=0.7, p=0.39
1-year	23, 3.1	14, 2.7	9, 3.9	x^2=0.7, p=0.39
Buprenorphine
Admission	25, 3.3	20, 3.9	5, 2.1	x^2=1.4, p=0.22
1-year	29, 3.9	23, 4.4	6, 2.6	x^2=1.4, p=0.22
Fentanyl
Admission	23, 3.1	17, 3.3	6, 2.6	x^2=0.2, p=0.60
1-year	39, 5.2	30, 5.8	9, 3.9	x^2=1.1, p=0.27
Methadone
Admission	2, 0.3	2, 0.4	–	x^2=0.9, p=0.34
1-year	8, 1.1	8, 1.5	–	x^2=3.6, p=0.06
Paracetamol
Admission	453, 60.2	298, 57.4	155, 66.5	x^2=5.5, p=0.01
1-year	429, 57.1	291, 56.1	138, 59.5	x^2=0.7, p=0.38
Celecoxib
Admission	99, 13.2	73, 14.1	26, 11.2	x^2=1.1, p=0.27
1-year	79, 10.5	51, 9.8	28, 12.1	x^2=0.8, p=0.35
NSAID
Admission	79, 10.5	55, 10.6	24, 10.3	x^2=0.01, p=0.90
1-year	55, 7.3	33, 6.4	22, 9.5	x^2=2.3, p=0.12
Steroid
Admission	25, 3.3	16, 3.1	9, 3.9	x^2=0.3, p=0.58
1-year	29, 3.9	17, 3.3	12, 5.2	x^2=1.5, p=0.21
Carbamazepine
Admission	2, 0.3	2, 0.4	–	x^2=0.9, p=0.34
1-year	5, 0.7	3, 0.6	2, 0.9	x^2=0.1, p=0.65
Neuromodulator
Admission	382, 50.8	245, 47.2	137, 58.8	x^2=8.6, p=0.003
1-year	393, 52.3	255, 49.1	138, 59.5	x^2=6.8, p=0.009
Antidepressants
Admission	46, 6.1	33, 6.4	13, 5.6	x^2=0.1, p=0.68
1-year	61, 8.1	37, 7.1	24, 10.3	x^2=2.2, p=0.13
	Mean, SD	Mean, SD	Mean, SD
Pain perception
Admission	2.5, 2.6	2.5, 2.7	2.3, 2.4	Time F=0.2, p=0.60
1-year	2.3, 2.5	2.3, 2.6	2.4, 2.5	TimexGroup F=1.4, p=0.23
Maximum pain perception
Admission	5.5, 3.1	5.5, 3.2	5.3, 3.0	Time F=10.8, p=0.001
1-year	4.9, 3.3	4.7, 3.3	5.2, 3.1	TimexGroup F=4.4, p=0.03

Data availability statement

The datasets generated and/or analyzed during the current study are available from the corresponding author on reasonable request.